FRI603 Treatment Of Severe Refractory Hypoglycemia Due To Malignant Insulinoma With A Novel Anti-insulin Receptor Antibody

Disclosure: S. Osataphan: None. M. Vamvini: None. E.D. Rosen: Consulting Fee; Self; Novartis Pharmaceuticals. L. Pei: None. N. Erlikh: None. G. Singh: None. P. Dhorajiya: None. J. Parker: None. J.M. Dreyfuss: None. A. Rattani: Stock Owner; Self; Vertex Pharmaceuticals, Provention Bio, Bluebird Bio,...

Descripción completa

Detalles Bibliográficos
Autores principales: Osataphan, Soravis, Vamvini, Maria, Rosen, Evan D, Pei, Lei, Erlikh, Natanie, Singh, Gurcharan, Dhorajiya, Poojaben, Parker, J Anthony, Dreyfuss, Jonathan M, Rattani, Ahmed, Patti, Mary-Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Diabetes And Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554945/
http://dx.doi.org/10.1210/jendso/bvad114.827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10554945/
http://dx.doi.org/10.1210/jendso/bvad114.827

Ejemplares similares